- March 23, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
tymlos
Synonyms :
abaloparatide
Class :
Parathyroid hormone analogue
Dosage Forms & Strengths
Subcutaneous injection
80mcg/40mcl
Men
80mcg subcutaneous everyday
Postmenopausal women
80mcg subcutaneous everyday
Dosage Forms & Strengths
Safety and efficacy not established
Refer adult dosing
It may decrease the effects of human parathyroid hormone
When levobupivacaine and abaloparatide are combined, the risk or seriousness of adverse events will rise
may increase the hypoglycemic effect of direct-acting viral agents
may increase the hypoglycemic effect of direct-acting antiviral agents
may enhance the hypoglycemic effect of beta blockers
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the hypoglycemic effect of salicylates
may increase the hypoglycemic effect of hypoglycemia-associated agents
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
relugolix/estradiol/norethindrone
may enhance the hypoglycemic effect
relugolix/estradiol/norethindrone
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
Frequency defined:
>10%
Men
Erythema injection site
Women
Hypercalciuria
Redness at the injection site
Edema at the injection site
1-10%
Men
Arthralgia
Increased serum uric acid
Pain at the injection site
Contusion
Diarrhea
Hypercalcemia
Bone pain
Dizziness
Swelling at the injection site
Orthostatic hypotension
Abdominal distension
Nausea
Abdominal pain
Post-marketing reports
Constipation
Insomnia
Pruritis
Muscle spasm
Bruising
Dyspnea
Vomiting
Asthenia
Malaise
lethargy
Pregnancy consideration: Not recommended for women with reproductive potential
Lactation: Not recommended for women with reproductive potential
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient information leaflet
Generic Name: abaloparatide
Pronounced:
Why do we use abaloparatide?
Abaloparatide (also known as Tymlos) is a medication approved for treating postmenopausal women with osteoporosis. Osteoporosis is when the bones become weak and brittle, making them more prone to fractures (breaks). Abaloparatide is a type of drug called a parathyroid hormone analog, which means it is similar in structure to a hormone produced by the parathyroid glands.
When injected under the skin, abaloparatide stimulates the production of new bone tissue, which can help to increase bone density and reduce the risk of fractures. It is typically used in people at high risk for fractures or who have not responded well to other osteoporosis medications. Abaloparatide is not a cure for osteoporosis, but it can help to manage the condition and reduce the risk of fractures.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
